ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
26 announcements
Divi's Laboratories Ltd reported revenue from operations of ₹3,676 Cr (+35.4% YoY) and net profit of ₹1,127 Cr (+63.6% YoY) for Q2 FY27.
Divi's Laboratories will hold a board meeting on November 07, 2026, to approve unaudited standalone and consolidated financial results for the quarter ended September 30, 2026.
Divis Laboratories Ltd has submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Regulation 31.
Immediate relatives of the company purchased 462 shares for a total consideration of Rs. 0.43 Crore in the open market.
Divis Laboratories Ltd reported a share pledge by Designated Person Nimmagadda Venkata Anirudh involving securities valued at ₹3.33 Crore. Additionally, Joshita Divi acquired shares worth ₹0.96 Crore via market purchase.
An immediate relative of a Divis Laboratories promoter bought equity shares worth ₹0.58 Crore through a market purchase.
Designated Person PRASAD Y.T.S. disclosed the release of two share pledges involving 2,734 equity shares. The combined transaction value of the released pledges is Rs. 2.56 Crore.
Designated person PRASAD Y.T.S. sold 6,234 equity shares of Divis Laboratories Ltd for ₹5.84 Crore via market sale.
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd via a market sale worth ₹0.19 Crore.
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd in a market transaction valued at ₹18.56 Lakh.
K. Sridevi, an immediate relative of the promoter, sold 200 shares of Divi's Laboratories for ₹0.19 Crore in a market transaction.
K. Sridevi, an immediate relative of a Divi's Laboratories promoter, sold 200 equity shares in a market transaction. The sale was valued at approximately ₹0.18 Crore.
Divi's Laboratories Limited held its 36th Annual General Meeting on August 10, 2026. All resolutions set out in the notice were passed with the requisite majority.
Divi's Laboratories showcases dominant market positioning in APIs and custom synthesis with ~$1.25B revenue, focusing on volume-led growth across 100+ countries.
Divi's Laboratories Ltd reported revenue from operations of ₹3,080 Cr (+27.8% YoY) and net profit of ₹902 Cr (+65.5% YoY) for Q1 FY27.
Divi's Laboratories Limited announced the retirement of Mr. L. Ramesh Babu (VP Procurement) and Mr. D. Madhu Babu (VP Projects), effective July 31, 2026.
Divis Laboratories Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. This routine regulatory disclosure details the distribution of equity shares.
Divi's Laboratories Limited announced a Board Meeting scheduled for August 01, 2026, to approve the financial results for the quarter ended June 30, 2026.
Divi’s Laboratories submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG performance and sustainability initiatives.
Divi's Laboratories convened its 36th AGM for August 10, 2026. Key agenda items include adopting financial statements and approving a ₹30 per share dividend.
Divi's Laboratories submitted its FY 2025-26 Annual Report and 36th AGM notice. The company reported a total income of Rs 10,894 Crore and PAT of Rs 2,607 Crore.
Divis reported FY26 revenue of ₹11,067 cr (up 14%) and PAT of ₹2,568 cr. Management focuses on expanding custom synthesis and peptide capabilities while navigating geopolitical logistics challenges.
Divi's Laboratories recommended a final dividend of Rs 30 per share for FY 2025-26. The record date is set for July 24, 2026.
Divi's Laboratories Ltd reported revenue from operations of ₹2,831 Cr (+9.5% YoY) and net profit of ₹751 Cr (+13.4% YoY) for Q4 FY26.
Divis Laboratories reported a consolidated annual net profit of ₹2,568 Crore. The board also recommended a final dividend of ₹30 per equity share.
Divi's Laboratories scheduled a board meeting for May 23, 2026, to approve audited yearly results and a final dividend. The trading window remains closed until May 25.